Telix was created to deliver on the promise of nuclear medicine.
Telix is a late-stage radiopharmaceutical company developing a broad portfolio of diagnostic and therapeutic (‘theranostic’) assets using Molecularly Targeted Radiation (MTR). Nuclear medicine is finally coming of age, with commercial critical mass building and commitment to late-stage product development. Our goal is to harness this momentum for the benefit of patients, with MTR potentially offering better-informed treatment decisions and truly personalised therapy.
Telix’s product development strategy is to closely integrate and add value to standard care, reflective of the modern team-based approach to managing cancer.
Telix’s research pipeline aims to address significant unmet medical need in prostate, kidney, brain (glioblastoma), and hematologic cancers as well as a range of immunologic and rare diseases. They are also keenly interested in partnership and in-licensing opportunities to further expand our portfolio.
Telix is headquartered in Melbourne, Australia with international operations in Belgium, Japan, Switzerland, and the United States. In 2020, Telix acquired a production facility in Seneffe, Belgium, with one of the broadest private sector medical isotope licences in Europe. This delivers significant operational flexibility, and ensures the ability to meet commercial production requirements in Europe.
We are incredibly proud to partner with the Telix team to transform care for Australian men impacted by prostate cancer.
For more information about Telix, click here.